All In Biotech

Drug Trial Radar · NCT05757713

Teplizumab in Pediatric Stage 2 Type 1 Diabetes

Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes (Participants <8 Years of Age With at Least Two Autoantibodies and Dysglycemia)

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

Jul 25, 2023

Primary completion

Aug 28, 2026

Study completion Aug 28, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are \<8 years of age.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • teplizumabBiological

    CD3-directed humanized monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs)Time frame: Through 104 Weeks

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • UCSF Medical Center Site Number : 107

    San Francisco, California

  • Barbara Davis Center for Diabetes Site Number : 102

    Aurora, Colorado

  • Yale University School of Medicine Site Number : 101

    New Haven, Connecticut

  • Centricity Research Site Number : 104

    Columbus, Georgia

  • Indianapolis University Health Riley Hospital for Children Site Number : 110

    Indianapolis, Indiana

  • UBMD Pediactrics Site Number : 105

    Buffalo, New York

  • Children's Hospital of Philadelphia Site Number : 108

    Philadelphia, Pennsylvania

  • Sanford Diabetes and Thyroid Clinic Site Number : 106

    Sioux Falls, South Dakota

  • Vanderbilt Univerity Medical Center Site Number : 109

    Nashville, Tennessee

  • MulitCare Institute for Research & Innovation Site Number : 103

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.